

## Noninvasive stent imaging with MSCT

Koen Nieman\*, MD, PhD

Departments of Cardiology & Radiology, Erasmus MC, Rotterdam, The Netherlands

The author has no conflict of interest to declare.

### KEYWORDS

Secondary coronary revascularisation, computed tomography, percutaneous coronary intervention, imaging

### Abstract

The fast development of multislice computed tomography (MSCT) for the study of the coronary arteries makes foreseeable its application in many of the aspects related to repeated coronary interventions after stent implantation. This refers not only to the assessment of long term results of stenting and the identification of restenosis, but also the relationship of the prosthesis to coronary locations, such as bifurcations, coronary ostia, etc., which might be relevant in planning secondary revascularisation.

In this article, the current state of the art of MSCT in assessing coronary stents is reviewed, paying attention to current technical limitations, to the available evidence on its use in different settings and to future applications in the context of improved MSCT and stent technologies.

\* Corresponding author: Erasmus MC, Thoraxcenter Bd 434, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

E-mail: koennieman@hotmail.com

© Europa Edition. All rights reserved.

## Introduction

Non-invasive coronary imaging by multislice computed tomography (MSCT) has rapidly developed over the past decade. The technique has become an accepted diagnostic option to rule out coronary artery disease in patients with stable anginal complaints. However, in patients who previously underwent percutaneous coronary intervention (PCI) CT angiography is challenged by metal-related high-attenuation artifacts, which compromise diagnostic accuracy.

## CT stent imaging

Computed tomography creates cross sectional images by calculating the regional roentgen attenuation of the scanned object. An iodine containing contrast medium is injected to create a difference in attenuation between the blood and the surrounding tissues, which then allows for the detection of luminal obstruction. Conventional stents cause significantly more attenuation than natural tissues or contrast-enhanced blood because of the high atomic number of the metals. This strong roentgen attenuation results in artifacts, which interferes with the interpretation of the in-stent lumen on contrast-enhanced MSCT angiography.

The diameter of the stent struts (0.07-0.14 mm) is considerably smaller than the three-dimensional CT image elements (voxels), which optimally measure  $\approx 0.4$  mm in all directions. Because of the very high contribution in attenuation by the stents struts, the averaged attenuation value (in Hounsfield units) within the voxel will be affected proportionally, and increase. Additionally, the CT data is filtered during the image reconstruction process to decrease image noise. This "smoothing" results in increased attenuation values caused by the stent to extend beyond the limits of the voxel with the stent material. Further blurring around the stent may result from residual motion artifacts. The combined consequence is a so-called blooming effect, which increases the apparent stent strut size, and artificially narrows the lumen within the stent as a consequence. Even under stationary, *in vitro* conditions, most of the lumen within the stent is affected by the adjacent stent, and results in artificial lumen narrowing of up to 40% even with 64-slice CT technology<sup>1</sup>. Another source of artifacts originates from the fact that the X-ray emitted from the roentgen tube is not monochromatic, but consists of a spectrum of frequencies with varying energy levels. The high-density material of the stent causes a disproportionate attenuation of low-energy photons, and a shift in the spectrum of the remaining

X-rays towards a higher energy level. This results in an interpreted lower attenuation and a dark appearance adjacent to the metal. This shadowing, which can also be found around calcifications, may be falsely interpreted as soft tissue within the stented lumen.

The magnitude and consequences of these artifacts are variable and depend on the stent size and design, patient characteristics and scanning conditions<sup>2</sup>. Depending on the atomic number and atomic density, the attenuation characteristics of different metals vary. In comparison to stainless steel and cobalt stents, tantalum stents, or gold or platinum markers cause more attenuation. In an *in vitro* study of 86 different coronary stents, Maintz et al, demonstrated that the artifact-free in-stent lumen is approximately 50%, but varies between 3% and 73% for specific stent types<sup>3</sup>. Depending on the strut thickness and the strut density of the stent design artifacts will increase. Because the extent of the blooming is fairly constant, the relative effect on interpretation of the in-stent lumen decreases with larger stent diameter.

Assessability of stents on CT can be increased by optimising the acquisition and reconstruction protocol (Figure 1). Reconstruction of thin slices with sharper filtering will decrease the blooming effect and increase the visible lumen within the stent<sup>3</sup>. Increased levels of image noise, which occur when reconstructing thinner slices with sharper filtering, may necessitate higher tube currents during scanning. Stent artifacts combined with motion artifacts are likely to render the in-stent lumen non-interpretable. The temporal resolution of current CT technology varies between 80 and 200 ms, which is a considerable improvement compared to earlier technology, but still insufficient in patients with a fast heart rate. Heart rate modulation is advised in patients with higher heart rate who need to be examined by MSCT, particularly when the patient previously underwent stent implantation. Somewhat higher heart rates may be tolerated using dual-source CT instead of conventional single-source technology.

## Detection of in-stent restenosis by MSCT

Most patients who underwent percutaneous coronary intervention in the past will need diagnostic angiography again at some point in time. Recurrent symptoms may (or may not) be caused by in-stent restenosis or disease progression in non-treated coronary branches. A noninvasive alternative to catheter angiography is desirable. Employing consecutive CT technology numerous studies have been published that investigated the diagnostic performance of CT




Figure 1. Dual-energy CT angiogram of a stent in a carotid artery reconstructed in four different ways: A) tube current 140 kV, slice thickness 0.6 mm, sharp kernel; B) 140 kV, 0.6 mm, softer kernel; C) 140 kV, thicker slices (1.0 mm), soft kernel; D) 80 kV, thin slices (0.6 mm), soft kernel.

angiography after previous coronary stenting<sup>4-20</sup>. Insufficient image quality required exclusion of up to 46% of the imaged stents. Sensitivity for the detection of in-stent restenosis varied between 67% and 100%, with a specificity between 74% and 100%. The heterogeneous results of these studies can at least in part be explained by differences in stents type and size, the relatively small populations and the variable prevalence of disease. Several authors reported better image interpretability and diagnostic performance in stents with larger diameters and thinner struts<sup>4,5,8,12-14,16,19</sup>. Often stents smaller than 3.0 mm are considered unlikely to be well interpretable. Stents made of tantalum and those containing gold are less interpretable compared to stents made of stainless steel and cobalt alloys<sup>8</sup>. It has also been demonstrated that stent fracture can be imaged<sup>21</sup>, however, less than severe stent malapposition is beyond the reach of current CT technology. In a meta-analysis of fourteen 16- and 64-slice CT studies by Vanhoenacker et al the pooled sensitivity to detect in-stent restenosis, after excluding 11% (95% CI: 4-20%) of the data, was 82% (72-89%), the specificity was 91% (83%-96%), pooled negative likelihood ratio and positive likelihood ratio were 0.20 (0.13-0.32) and 9.34 (4.68-18.62), respectively<sup>22</sup>. The authors could demonstrate that the exclusion rate was influenced by the number of detectors, stent diameter, strut thickness and the use of sharp filtering. Including a number of recent 64-slice and dual-source CT studies, Table 1 suggests that the sensitivity of 64-slice CT has improved to  $\geq 90\%$ . While the prevalence of in-stent restenosis varies between 6 and 49%, the proportion of complete occlusion is often high (25-59%). Stent occlusion is easier recognised than in-stent stenosis (Figure 2). For those papers reporting separate results for occlusion and stenosis, pooled analysis shows that all occlusions are detected (sensitivity 100%), while only 82% of the 50-99% stenosis are




Figure 2. Three-vessel stenting with diffuse in-stent hyperplasia of an extensively treated right coronary artery (RCA, A and D), a fully patent left anterior descending coronary artery (LAD) with two stents (B, D, E), and an occluded stent in the left circumflex branch (LCX) with the distal lumen filled via collaterals (C and E). Note the preserved septal branch (panel B).

Table 1. Segmental diagnostic accuracy of MSCT to detect in-stent restenosis.

	CT	N	Stents	Prev (#)	Excl.	Sens	Spec	PPV	NPV
Schuijf, et al (2004) <sup>4</sup>	16x0.5 mm	22	65	14%	23%	78%	100%	100%	95%
Gilard, et al (2005) <sup>5</sup>	16x0.75 mm	143	232	6%	47%	77%	100%	62%	98%
Caspar, et al (2005) <sup>6</sup>	40x0.63 mm	65	111	24% (37%)	-	74%	83%	59%	91%
Cademartiri, et al (2005) <sup>7</sup>	16x0.75 mm	51	76	8% (50%)	1%	83%	99%	83%	97%
Kitagawa, et al (2006) <sup>8</sup>	16x0.63 mm	42	61	12% (25%)	31%	100%	100%	100%	100%
Chabbert, et al (2006) <sup>9</sup>	16x0.75 mm	114	NR	23%	13%	92%	67%	43%	97%
Rist, et al (2006) <sup>10</sup>	64x0.6 mm	25	46	18% (25%)	2%	75%	92%	67%	94%
Van Mieghem, et al (2007) <sup>*11</sup>	64x0.6 mm	64	162	6%	21%	100%	91%	67%	100%
Cademartiri, et al (2007) <sup>12</sup>	64x0.6 mm	182	192	11% (35%)	7%	95%	93%	63%	99%
Rixe, et al (2007) <sup>13</sup>	64x0.6 mm	64	102	12%	42%	89%	98%	86%	98%
Oncel, et al (2007) <sup>14</sup>	64x0.6 mm	30	39	49% (47%)	-	89%	95%	94%	90%
Das, et al (2007) <sup>15</sup>	64x0.6 mm	53	110	28% (13%)	9%	97%	88%	78%	99%
Pugliese, et al (2007) <sup>16</sup>	64x0.6 mm (DSCT)	100	178	39% (23%)	5%	94%	92%	77%	98%
Ehara, et al (JACC 2007) <sup>17</sup>	64x0.6 mm	81	125	20%	12%	91%	93%	77%	98%
Carrabba et al (AJC 2007) <sup>18</sup>	64x0.63 mm	41	87	15% (54%)	-	84%	97%	92%	97%
Hecht, et al (AJC 2008) <sup>19</sup>	64x0.63 mm	67	132	13% (59%)	-	94%	74%	39%	99%
Manghat, et al (AJC 2008) <sup>20</sup>	64x0.63 mm	40	103	20%	10%	85%	86%	61%	96%

Detector collimation (CT) as number of detectors/acquisitions x individual detector width (mm), population (N), prevalence of in-stent restenosis (prev.) with proportion of total occlusion between brackets (when reported), exclusion rate (excl.), sensitivity (sens), specificity (spec), positive predictive value (PPV) and negative predictive value (NPV) to detect significant in-stent restenosis, generally defined as >50% lumen reduction. \*Left main stenting. Not reported (NR). Dual-source CT (DSCT)

identified<sup>6,7,10,12,14,15</sup>. Due to the blooming artifact, a minimal amount of neointimal hyperplasia is required for it to be recognised on CT. Van Mieghem et al showed with IVUS that the minimal amount of neointimal hyperplasia was at least 1 mm<sup>11</sup>, Manghat et al concluded from angiographic comparisons that <30% in-stent stenosis could not be well recognised on MSCT<sup>20</sup>. Although the diagnostic performance of current CT technology is improving, results are still considered insufficient for positive recommendations of unrestricted use of CT coronary angiography in patients with coronary stents<sup>23,24</sup>.

### CT after left main stenting

Despite the known challenges, limited evidence suggests that severe obstruction of larger stents in the proximal coronary branches can be performed reliably using state-of-the-art CT technology. In this respect, a patient population of particular interest are those who underwent stenting of the left main coronary artery. Considering the challenges of noninvasive detection of left main in-stent restenosis by means of exercise testing or perfusion imaging, as well as the potentially disastrous consequences of unrecognised obstruction of the left main coronary artery, most patients will be subjected to invasive coronary angiography 3-6 months after the intervention. Because of the large diameter size of the left main coronary artery the in-stent lumen can be assessed well by MSCT in most cases (Figure 3). Van Mieghem et al, examined 74 patients after left main stenting using 16 and 64-slice CT, with stent diameters varying between 3.0 and 3.5 mm. In 70 patients, with sufficient image quality, all significant stenoses were detected, the specificity was 91%. Lower specificity was found in patient who underwent complex bifurcation stenting (80%), in comparison to patients after simple stenting (97%)<sup>11</sup>. This suggests that the use of CT can obviate the need for invasive angiography in the majority of patients. Furthermore, in those cases in which the stent was deployed in the ostium with partial protrusion of the prosthesis in the aorta, MSCT can avoid not only the difficulties of selective coronary catheterisation, but also the inherent risk of stent damage or deformation by the coronary catheter seen in such attempts. Finally, and following the considerations already made in a previous chapter about MSCT in surgical grafts in this same issue, the large diameter size and relative immobility of surgical grafts makes assessment of stents in these conduits well possible<sup>6</sup> (Figure 4).



Figure 3. Assessment of a coronary stent implanted in the left main coronary artery. Despite significant coronary calcification, patency of the stent (arrow) can still be established.




Figure 4. Saphenous vein graft from the aorta to the LAD. Two stents (arrow heads) are well interpretable, and apparently without significant in-stent restenosis. Between the both stents progressive graft disease can be observed (arrow).

### Future development

CT innovations in terms of smaller detectors to reduce volume averaging and blooming, higher temporal resolution to reduce motion artifacts, dedicated filtering during image reconstruction, will continue to improve the interpretation of coronary stents. Improvements in stent design may also benefit non-invasive CT follow-up. Currently available stents with thinner struts show less blooming. Recently developed non-metallic, biodegradable stents are largely invisible on CT and allow reliable non-invasive follow-up by cardiac CT (Figure 5)<sup>25</sup>.




Figure 5. Marginal branch (RM) treated with a biodegradable, polylactic acid stent (BVS stent, Abbott Vascular, Redwood City, CA, USA), and overlapping conventional metal stent. The metal stent (arrow) causes extensive blooming, particularly on the maximum intensity projection image (MIP, B). The non-metal stent is invisible on CT except for the two radiopaque, platinum markers (arrow heads) at both ends of the stent. Mixed plaque on one side of the proximal marginal branch can still be appreciated. Multiplanar reformation (MPR).



## References

- Seifarth H, Ozgün M, Raupach R, Flohr T, Heindel W, Fischbach R, Maintz D. 64- Versus 16-slice CT angiography for coronary artery stent assessment: in vitro experience. *Invest Radiol.* 2006 Jan;41(1):22-7.
- Nieman K, Cademartiri F, Raaijmakers R, Pattynama P, de Feyter P. Noninvasive angiographic evaluation of coronary stents with multi-slice spiral computed tomography. *Herz.* 2003 Mar;28(2):136-42.
- Maintz D, Seifarth H, Raupach R, Flohr T, Rink M, Sommer T, Ozgün M, Heindel W, Fischbach R. 64-slice multidetector coronary CT angiography: in vitro evaluation of 68 different stents. *Eur Radiol.* 2006 Apr;16(4):818-26.
- Schuijff JD, Bax JJ, Jukema JW, Lamb HJ, Warda HM, Vliegen HW, de Roos A, van der Wall EE. Feasibility of assessment of coronary stent patency using 16-slice computed tomography. *Am J Cardiol.* 2004 Aug 15;94(4):427-30.
- Gilard M, Cornily JC, Pennec PY, Le Gal G, Nonent M, Mansourati J, Blanc JJ, Boschat J. Assessment of coronary artery stents by 16 slice computed tomography. *Heart.* 2006 Jan;92(1):58-61.
- Gaspar T, Halon DA, Lewis BS, Adawi S, Schliamsr JE, Rubinshtein R, Flugelman MY, Peled N. Diagnosis of coronary in-stent restenosis with multidetector row spiral computed tomography. *J Am Coll Cardiol.* 2005 Oct 18;46(8):1573-9.
- Cademartiri F, Mollet N, Lemos PA, Pugliese F, Baks T, McFadden EP, Krestin GP, de Feyter PJ. Usefulness of multislice computed tomographic coronary angiography to assess in-stent restenosis. *Am J Cardiol.* 2005 Sep 15;96(6):799-802.
- Kitagawa T, Fujii T, Tomohiro Y, Maeda K, Kobayashi M, Kunita E, Sekiguchi Y. Noninvasive assessment of coronary stents in patients by 16-slice computed tomography. *Int J Cardiol.* 2006 May 10;109(2):188-94.
- Chabbert V, Carrie D, Bennaceur M, Maupas E, Lauwers V, Mhem M, Lhermusier T, Elbaz M, Joffre F, Rousseau H, Puel J. Evaluation of in-stent restenosis in proximal coronary arteries with multidetector computed tomography (MDCT). *Eur Radiol.* 2007 Jun;17(6):1452-63.
- Rist C, von Ziegler F, Nikolaou K, Kirchin MA, Wintersperger BJ, Johnson TR, Knez A, Leber AW, Reiser MF, Becker CR. Assessment of coronary artery stent patency and restenosis using 64-slice computed tomography. *Acad Radiol.* 2006 Dec;13(12):1465-73.
- Van Mieghem CA, Cademartiri F, Mollet NR, Malagutti P, Valgimigli M, Meijboom WB, Pugliese F, McFadden EP, Ligthart J, Runza G, Bruining N, Smits PC, Regar E, van der Giessen WJ, Sianos G, van Domburg R, de Jaegere P, Krestin GP, Serruys PW, de Feyter PJ. Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound. *Circulation.* 2006 Aug 15;114(7):645-53.
- Cademartiri F, Schuijff JD, Pugliese F, Mollet NR, Jukema JW, Maffei E, Kroft LJ, Palumbo A, Ardissino D, Serruys PW, Krestin GP, Van der Wall EE, de Feyter PJ, Bax JJ. Usefulness of 64-slice multislice computed tomography coronary angiography to assess in-stent restenosis. *J Am Coll Cardiol.* 2007 Jun 5;49(22):2204-10.
- Rixe J, Achenbach S, Ropers D, Baum U, Kuettner A, Ropers U, Bautz W, Daniel WG, Anders K. Assessment of coronary artery stent restenosis by 64-slice multi-detector computed tomography. *Eur Heart J.* 2006 Nov;27(21):2567-72.
- Oncel D, Oncel G, Tastan A, Tamci B. Evaluation of coronary stent patency and in-stent restenosis with dual-source CT coronary angiography without heart rate control. *AJR Am J Roentgenol.* 2008 Jul;191(1):56-63.
- Das KM, El-Menyar AA, Salam AM, Singh R, Dabdoob WA, Albinai HA, Al Suwaidi J. Contrast-enhanced 64-section coronary multidetector CT angiography versus conventional coronary angiography for stent assessment. *Radiology.* 2007 Nov;245(2):424-32.
- Pugliese F, Weustink AC, Van Mieghem C, Alberghina F, Otsuka M, Meijboom WB, van Pelt N, Mollet NR, Cademartiri F, Krestin GP, Hunink MG, de Feyter PJ. Dual source coronary computed tomography angiography for detecting in-stent restenosis. *Heart.* 2008 Jul;94(7):848-54.
- Ehara M, Kawai M, Surmely JF, Matsubara T, Terashima M, Tsuchikane E, Kinoshita Y, Ito T, Takeda Y, Nasu K, Tanaka N, Murata A. Diagnostic accuracy of coronary in-stent restenosis using 64-slice computed tomography: comparison with invasive coronary angiography. Fujita H, Sato K, Kodama A, Katoh O, Suzuki T. *J Am Coll Cardiol.* 2007 Mar 6;49(9):951-9.
- Carrabba N, Bamoshmoosh M, Carusi LM, Parodi G, Valenti R, Migliorini A, Fanfani F, Antonucci D. Usefulness of 64-slice multidetector computed tomography for detecting drug eluting in-stent restenosis. *Am J Cardiol.* 2007 Dec 15;100(12):1754-8.
- Hecht HS, Zaric M, Jelnin V, Lubarsky L, Prakash M, Roubin G. Usefulness of 64-detector computed tomographic angiography for diagnosing in-stent restenosis in native coronary arteries. *Am J Cardiol.* 2008 Mar 15;101(6):820-4.
- Manghat N, Van Lingen R, Hewson P, Syed F, Kakani N, Cox I, Roobottom C, Morgan-Hughes G. Usefulness of 64-detector row computed tomography for evaluation of intracoronary stents in symptomatic patients with suspected in-stent restenosis. *Am J Cardiol.* 2008 Jun 1;101(11):1567-73.
- Lim HB, Hur G, Kim SY, Kim YH, Kwon SU, Lee WR, Cha SJ. Coronary stent fracture: detection with 64-section multidetector CT angiography in patients and in vitro. *Radiology.* 2008 Dec;249(3):810-9.
- Vanhoenacker PK, Decramer I, Bladt O, Sarno G, Van Hul E, Wijns W, Dwamena BA. Multidetector computed tomography angiography for assessment of in-stent restenosis: meta-analysis of diagnostic performance. *BMC Med Imaging.* 2008 Jul 31;8:14.
- Schroeder S, Achenbach S, Bengel F, Burgstahler C, Cademartiri F, de Feyter P, George R, Kaufmann P, Kopp AF, Knuuti J, Ropers D, Schuijff J, Tops LF, Bax JJ; Working Group Nuclear Cardiology and Cardiac CT; European Society of Cardiology; European Council of Nuclear Cardiology. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. *Eur Heart J.* 2008 Feb;29(4):531-56.
- Bluemke DA, Achenbach S, Budoff M, Gerber TC, Gersh B, Hillis LD, Hundley WG, Manning WJ, Prantz BF, Stuber M, Woodard PK. Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the American heart association committee on cardiovascular imaging and intervention of the council on cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular disease in the young. *Circulation.* 2008 Jul 29;118(5):586-606.
- Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. *Lancet.* 2008 Mar 15;371(9616):899-907.